Pediatric chronic myelogenous leukemia is uncommon. We report a pediatric patient with chronic myelogenous leukemia presenting with a normal white blood cell count and no circulating immature myeloid cells. The patient presented with extreme thrombocytosis (platelet count range: 2175-3064 Â 10 9 /L) noted incidentally. No splenomegaly was found. Examination of the bone marrow aspirate revealed normal cellularity and normal myeloid: erythroid ratio with marked megakaryocytic hyperplasia. Molecular studies on the bone marrow aspirate detected both the major BCR/ABL1 p210 fusion transcript (9280 copies; p210/ABL1 ratio: 38.2%) and the minor p190 transcript (below limit of quantitation). The platelet count normalized within 2 weeks after treatment with the second-generation tyrosine kinase inhibitor dasatinib. Follow-up after 3 months revealed a 1.87 log reduction in p210 transcripts compared to diagnosis and no detectable p190 transcripts. This case highlights the need to include BCR/ABL1 fusion testing to accurately diagnose pediatric patients presenting with isolated thrombocytosis.
Introduction
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by the presence of the BCR/ABL1 fusion transcript encoded by the Philadelphia (Ph) chromosome, a result of a reciprocal translocation between chromosomes 9 and 22. Adult and pediatric CML are often considered similar diseases, but recent data highlight distinct biological differences between the two.
CML is more common in adults (median age 56 years) and constitutes approximately 12% of all adult leukemias.
1 Pediatric CML is rare representing only 2% of all leukemias in children younger than 14 years of age. 2 The median age at diagnosis in pediatric patients is around 12.5 years (range: 1-18 years) with most patients being older than 10 years of age. Pediatric CML patients typically have higher mean WBC counts (242 Â 10 9 /L; range: 12-720 Â 10 9 /L), more pronounced splenomegaly, and pursue a more aggressive clinical course when compared to adult CML patients. 3 Although adult and pediatric CML patients harbor BCR/ABL1 fusion products by definition, Krumbholz et al. 4 showed that there are differences in the BCR breakpoint distribution. Children with chronic phase CML (CML-CP) have a higher proportion of breakpoints within Alu repeat regions compared to adults with CML. 4 This distribution is similar to the pattern observed in adult Ph-positive (Phþ) acute lymphoblastic leukemia with p210 rearrangement. 5 In adults, the clinical presentation of adult CML is partly influenced by the type of BCR/ABL1 fusion transcript detected. For example, the p210 b3/a2 transcript that includes BCR exon 14 is associated with a higher platelet count at diagnosis relative to the p210 b2/a2 transcript that excludes BCR exon 14. 6 Also, patients that coexpress the p210 and p190 fusion transcripts typically present with higher platelet counts than patients with the p210 transcript alone. 7 Phþ cases of CML with an essential thrombocythemia (ET) like presentation have previously been reported in adults, and many of these cases were referred to as Phþ cases of ET prior to the 2001 World health organization/polycythemia vera study group classification of hematopoietic tumors. Such cases occur predominantly in adult female patients, harbor additional cytogenetic changes, and exhibit a poorer response to therapy. 8 In contrast, CML with thrombocythemic onset mimicking ET is considered rare in adults and has not been reported in pediatric patients. The rare, reported adult cases of CML mimicking ET often occurred in females with modestly elevated WBC counts and a proportion of immature myeloid cells in circulation. 8 Here, we report an unusual case of CML mimicking ET in a male pediatric patient who presented with a significantly elevated platelet count, a normal white blood count, without circulating immature myeloid cells, and absent splenomegaly. The patient's response to treatment and immediate clinical course are also discussed.
Case
A previously healthy 9-year-old male patient presented to an outside physician with complaints of recent onset of cough of 10 days duration, fatigue, frequent headache, dizziness, and notable bruising. His past medical and surgical history were significant only for frequent otitis media and tympanostomy tube insertion. His hematologic family history was significant for acute leukemia in a paternal uncle at 8 years of age and Hodgkin disease in a maternal grandfather. A diagnosis of sinusitis was entertained and the patient was prescribed azithromycin. However, a complete blood count (CBC) drawn during the visit revealed a markedly elevated platelet count of 2175 Â 10 9 /L, confirmed on repeat CBC (3064 Â 10 9 /L). He was then referred to our tertiary care academic pediatric hospital for evaluation of his extreme thrombocytosis.
Physical examination performed at our institution was unremarkable and revealed no abnormalities. Notably, his ocular and nasal exams were within normal limits, no splenomegaly was detected (ultrasound was not performed for splenomegaly), and no petechiae or bruising were evident despite the subjective complaint. His blood indices drawn at time of presentation are shown (Table 1) . Clinical diagnostic considerations included ET, familial thrombocytosis, and endogenous thrombopoietin (TPO) secretion. A bone marrow biopsy and additional laboratory data were requested by the clinical team. The CBC values at diagnosis and 3 months after therapy are illustrated in Table 1 . At diagnosis, mature neutrophils accounted for only half of circulating leukocytes and no immature myeloid cells or bands were seen, and there was notable absolute basophilia.
Bone marrow examination revealed a normocellular marrow for age (70%-80%) with a normal myeloid:erythroid (M:E) ratio of 4:1 ( Figure 1 ). There was marked megakaryocytic hyperplasia with focal areas of loose clustering. There were significant numbers of monolobated and dwarf megakaryocytes. No hyperlobated, large or giant forms of megakaryocytes were seen. There was no increase in the paratrabecular cuff of immature myeloid cells typically seen in CML. A reticulin stain did not show increased reticulin fibrosis.
Additional laboratory data revealed low TPO levels (<7 pg/mL; reference: 7-99 pg/mL) arguing against endogenous TPO secretion. Molecular studies were performed to exclude diagnostic markers of ET and no JAK2 p.V617F mutation (by allele specific real-time polymerase chain reaction [PCR] with hydrolysis probes), MPL exon 10 mutations (by PCR amplification, direct sequencing of coding and junctional regions of exon 10 in the absence and presence of a probe that suppresses amplification of wild-type MPL codon 515), or CALR exon 9 (by PCR amplified, bidirectional sequencing of coding regions and intron-exon junctions of exon 9 of the CALR gene) mutations were detected. However, concomitant molecular studies using quantitative reversetranscriptase PCR (qRT-PCR) detected BCR/ABL1 fusion transcripts: a predominant p210 transcript at a BCR/ABL ratio of approximately 38.2%, and a p190 BCR/ABL1 transcript that was detected below the level of quantitation (our PCR methodology detects but does not distinguish either of the two p210 variants-b3/a2 and b2/a2). Conventional karyotyping revealed a typical t(9;22)(q34;q11), Ph chromosome, without any additional cytogenetic abnormalities in all (20/20, 100%) of cells examined. A fluorescence in situ hybridization study using a BCR/ABL1 dual color, dual fusion probe set revealed a BCR/ABL1 fusion pattern, indicating t(9;22) in 160 out of 200 (80%) interphase cells examined. A diagnosis of CML was therefore rendered. The patient was treated with dasatinib (60/m 2 /day) daily and aspirin 81 mg daily. At 3 months after diagnosis he had shown complete hematologic remission with platelet count dropping to normal within 2 weeks of therapy. He did experience frequent abdominal pain and mild neutropenia possibly related to his therapy. Repeat qRT-PCR testing for BCR/ABL at 3 months revealed a 1.87 log reduction in the p210 transcript and no evidence of the p190 transcript. The patient reported marked clinical improvement thus far and had returned to normal functioning of daily activity. Recent repeat qRT-PCR testing (9 months after diagnosis) revealed a major molecular response with 3.4 log reduction in p210 transcripts and the patient remains clinically stable.
Discussion
In this report, we describe a rare case of CML diagnosed in a male pediatric patient who presented with a normal white blood cell count, no neutrophilic leukocytosis, no circulating immature myeloid cells, and severe thrombocytosis. This presentation has been referred to as either as CML with thrombocythemic onset. Previous reports described CML with ET-like presentations in adults, with a preponderance of female patients, and this has been associated with a poorer prognosis relative to cases of typical CML in chronic phase. 8 However, this unusual CML presentation in the pediatric age group is not well described. Normal white blood cell counts are unusual in CML and even when counts are low, there is almost always a component of immature myeloid cells. Basophilia, which is considered an invariable finding in cases of CML, was also present in this case.
The presentation of thrombocytosis in pediatric patients raises multiple differential diagnoses. Most cases of thrombocytosis in children are a result of secondary processes rather than primary processes. Most secondary cases tend to have mild to moderate platelet increases rather than the marked thrombocytosis seen in primary causes (Table 2) . 9, 10 Secondary causes can, however, transiently reach levels of 900,000.
11 This patient had a normal erythrocyte sedimentation rate, normal iron studies, and very high platelet count ruling out common secondary causes and suggesting a primary thrombocytosis.
ET and hereditary thrombocytosis are common primary causes of thrombocytosis. Molecular studies for JAK2, MPL, and CALR mutations were all negative and TPO levels were decreased as would be expected for most cases of thrombocytosis, except when there is excessive endogenous production of TPO or in certain familial thrombocytosis in which case TPO is increased.
11
A positive BCR/ABL1 transcript is diagnostic of CML according to the current 2008 WHO classification of hematopoietic neoplasms. 12 Prior to 2001, it was thought that a minority of patients with ET could also have BCR/ ABL1 transcripts and that some cases of ET were capable of transforming to CML. 13 Further longitudinal studies disapproved this, since cases that were BCR/ABL1 positive tended to have similar prognosis to CML patients (prior to TKI therapy) rather than a more benign course expected for ET patients.
The BCR/ABL1 fusion transcript is usually found in all myeloid cells and also in monocytes, megakaryocytes, and endothelial cells. In CML, other cell lineages may therefore exhibit proliferative activity, sometimes preferentially, leading to clinical pictures mimicking other myeloproliferative disorders like chronic myelomonocytic leukemia or ET. The bone marrow exam can be helpful in the differential diagnosis, however sometimes, as illustrated in this case, biopsy findings may not be typical of CML. This case lacked the typical morphologic features of CML, such as an increase in M:E ratio, increased paratrabecular cuffs of immature cells and the myelocyte bulge. 12 A morphologic clue to the diagnosis of CML was the dwarf megakaryocytes and the bone marrow basophilia; lack of large, multilobated megakaryocytes, features typically seen in ET were not present in our case, hence argued against a diagnosis of ET.
At a molecular level, higher platelet counts have been associated with the b3/a2 variant of p210 14 and similarly to our patient have also been associated with coexpression of p210/p190 BCR/ABL transcripts. 7 Our patient's p210 transcript levels (38.2%) were relatively low at diagnosis, and this is consistent with previous reports of adult ET-like CML. 15 Some reports of adult patients with CML with thrombocythemic onset and the b3/a2 transcript variant have reported additional cytogenetic abnormalities apart from Ph chromosome; making some authors attribute the slightly poorer prognosis in these patients relative to typical CML to this finding. 16 Molecular factors influencing normal WBC counts are not clearly defined but may also result from differential kinase activity or differential activity in other motifs influencing cell adhesion. 17 In this case, the normal WBC count and normal M:E ratio may suggest decreased proliferation and relatively intact cell adhesion in the neutrophil series or over expression of certain cytokines.
In conclusion, we report an unusual case of CML in a male pediatric patient presenting with a markedly elevated platelet count without neutrophilia or any circulating immature myeloidcell component, and with no splenomegaly. This presentation can pose a diagnostic dilemma and underscores the need to evaluate for BCR/ ABL1 fusion transcripts in all pediatric cases presenting with marked thrombocytosis. Our case also emphasizes the absolute need to rule out the presence of BCR/ABL transcripts whenever a differential diagnostic consideration is made for myeloproliferative neoplasm or myeloproliferative/myelodysplastic syndromes. The patient has so far responded very well to targeted dasatinib therapy and follow-up of his disease course will be important as an index case of this form of CML presentation in this age group.
